Respiratory syncytial virus, or RSV, is a common infection among both infants and older people that can lead to dangerous inflammation of the lungs and contributes to up to 240,000 hospitalizations in the U.S. annually. But until this year, there wasn’t a vaccine to protect against the virus. Now, there are several. In May, the FDA approved GSK’s Arexvy for adults over age 60, and followed with approval of Abrysvo from Pfizer for the same age group. In August, the agency approved the same Pfizer vaccine for pregnant women in order to protect newborns. And kids under age two whose moms weren’t vaccinated can now take advantage of Sanofi Pasteur’s Beyfortus, a one-time, injected antibody therapy that the FDA approved in July and improves on the previous treatment that required multiple shots throughout the winter season.
- How Donald Trump Won
- The Best Inventions of 2024
- Why Sleep Is the Key to Living Longer
- Robert Zemeckis Just Wants to Move You
- How to Break 8 Toxic Communication Habits
- Nicola Coughlan Bet on Herself—And Won
- Why Vinegar Is So Good for You
- Meet TIME's Newest Class of Next Generation Leaders
